| Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study JS Abramson, ML Palomba, LI Gordon, MA Lunning, M Wang, J Arnason, ... The Lancet 396 (10254), 839-852, 2020 | 2012 | 2020 |
| Ibrutinib in previously treated Waldenström’s macroglobulinemia SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ... New England Journal of Medicine 372 (15), 1430-1440, 2015 | 1035 | 2015 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 435 | 2021 |
| Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma CH Moskowitz, H Schöder, J Teruya-Feldstein, C Sima, A Iasonos, ... Journal of clinical oncology 28 (11), 1896-1903, 2010 | 399 | 2010 |
| Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma C Grommes, A Pastore, N Palaskas, SS Tang, C Campos, D Schartz, ... Cancer discovery 7 (9), 1018-1029, 2017 | 387 | 2017 |
| Rituximab plus lenalidomide in advanced untreated follicular lymphoma F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ... New England Journal of Medicine 379 (10), 934-947, 2018 | 386 | 2018 |
| Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 339 | 2018 |
| PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's … AJ Moskowitz, H Schöder, J Yahalom, SJ McCall, SY Fox, J Gerecitano, ... The lancet oncology 16 (3), 284-292, 2015 | 304 | 2015 |
| Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer T Varughese, Y Taur, N Cohen, ML Palomba, SK Seo, TM Hohl, ... Clinical Infectious Diseases 67 (5), 687-692, 2018 | 263 | 2018 |
| Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma AJ Moskowitz, PA Hamlin Jr, MA Perales, J Gerecitano, SM Horwitz, ... Journal of Clinical Oncology 31 (4), 456-460, 2013 | 258 | 2013 |
| Active immunotherapy: current state of the art in vaccine approaches for NHL ML Palomba Current oncology reports 14, 433-440, 2012 | 252 | 2012 |
| Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies T Jain, A Knezevic, M Pennisi, Y Chen, JD Ruiz, TJ Purdon, SM Devlin, ... Blood advances 4 (15), 3776-3787, 2020 | 243 | 2020 |
| Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape C DeSelm, ML Palomba, J Yahalom, M Hamieh, J Eyquem, ... Molecular Therapy 26 (11), 2542-2552, 2018 | 227 | 2018 |
| Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma K Wudhikarn, ML Palomba, M Pennisi, M Garcia-Recio, JR Flynn, ... Blood cancer journal 10 (8), 79, 2020 | 209 | 2020 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 201 | 2022 |
| Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. JS Abramson, LI Gordon, ML Palomba, MA Lunning, JE Arnason, ... Journal of clinical oncology 36 (15_suppl), 7505-7505, 2018 | 200 | 2018 |
| Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors E Wang, X Mi, MC Thompson, S Montoya, RQ Notti, J Afaghani, ... New England Journal of Medicine 386 (8), 735-743, 2022 | 180 | 2022 |
| Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia SP Treon, K Meid, J Gustine, G Yang, L Xu, X Liu, CJ Patterson, ... Journal of Clinical Oncology 39 (6), 565-575, 2021 | 158 | 2021 |
| Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, ... Journal of Clinical Oncology 39 (28), 3109-3117, 2021 | 156 | 2021 |
| Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia L Xu, ZR Hunter, N Tsakmaklis, Y Cao, G Yang, J Chen, X Liu, S Kanan, ... British journal of haematology 172 (5), 735-744, 2016 | 155 | 2016 |
